Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.38 |
| ▸ | HTR2B | P41595 | 5/20 | 0.38 |
| ▸ | PAICS | P22234 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20231735 | 0.72 | TIPARP (0.50) | HTR2CHTR2B | |
| SCHEMBL4823398 | 0.71 | HTR2C (0.48) | HTR2CHTR2BCHRNB2CHRNA4 | |
| SCHEMBL13560051 | 0.71 | HTR2C (0.48) | HTR2CHTR2BCHRNB2CHRNA4 | |
| SCHEMBL28664212 | 0.67 | CHRNB2 (0.55) | CHRNB2CHRNA4PRKCZ | |
| SCHEMBL28664210 | 0.67 | CHRNB2 (0.55) | CHRNB2CHRNA4PRKCZ | |
| SCHEMBL6304017 | 0.66 | CHRNB2 (0.57) | HTR2CHTR2BCHRNB2CHRNA4PRKCZ | |
| SCHEMBL19023755 | 0.66 | HRH1 (0.49) | CHRNB2CHRNA4PRKCZ | |
| SCHEMBL4828298 | 0.66 | CHRNB2 (0.47) | HTR2CHTR2BCHRNB2CHRNA4PRKCZ | |
| SCHEMBL18077122 | 0.66 | TDO2 (0.52) | HTR2CHTR2BCHRNB2CHRNA4PRKCZ | |
| SCHEMBL28671432 | 0.66 | TDO2 (0.52) | HTR2CHTR2BCHRNB2CHRNA4PRKCZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647698-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647698-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | MDM2, CRBN, VHL | HTR2C 739/4885HTR2B 1955/4885PAICS 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.